Hans Wigzell, MD, PhD, has served as a member of our Board since June 2010. He serves as Chair of the Research and Development committee and as a member of the Nominating and Corporate Governance committee.
In the past 5 years, Dr. Wigzell has served as a Director of Probi AB, Swedish Orphan Biovitrum AB, and Valneva SE (a successor to Intercell AG), and currently serves as Chairman of Rhenman & Partners Asset Management AB, an investment management firm, and a Director of RaySearch Laboratories AB, a medical technology company. Since 2006, Dr. Wigzell has served as Chairman of Karolinska Development AB, a company listed on the NASDAQ OMX Stockholm market that seeks ways to commercialize promising Nordic life science innovations.
Dr. Wigzell was President of the Karolinska Institute, a medical university, from 1995 to 2003, and was General Director of the National Bacteriological Laboratory in Stockholm from 1987 to 1993. He is Chairman of the board of the Stockholm School of Entrepreneurship and an elected member of several national academies. These include the Swedish Royal Engineering Academy, the Swedish Royal Academy of Science, the Danish Academy of Arts and Letters, the American Academy of Arts and Sciences, the Finnish Science Society, and the European Molecular Biology Organization.
Dr. Wigzell’s academic career includes serving as Chairman of the Nobel Prize committee and the Karolinska Institute. He is Distinguished External Advisory Professor of Ehime University, Japan. He was appointed Chairman of the Nobel Assembly in 2000.
Dr. Wigzell holds an MD and PhD from the Karolinska Institute in Stockholm, along with honorary doctorate degrees at Tor Vergata University in Rome, Turku University in Finland, and The Feinstein Institute in New York.
What is Hans Rudolf Wigzell's net worth?
The estimated net worth of Hans Rudolf Wigzell is at least $2.61 million as of March 8th, 2024. Dr. Wigzell owns 22,840 shares of Sarepta Therapeutics stock worth more than $2,609,013 as of November 23rd. This net worth estimate does not reflect any other assets that Dr. Wigzell may own. Learn More about Hans Rudolf Wigzell's net worth.
How do I contact Hans Rudolf Wigzell?
Has Hans Rudolf Wigzell been buying or selling shares of Sarepta Therapeutics?
Hans Rudolf Wigzell has not been actively trading shares of Sarepta Therapeutics during the last ninety days. Most recently, Hans Lennart Rudolf Wigzell sold 15,000 shares of the business's stock in a transaction on Friday, March 8th. The shares were sold at an average price of $123.25, for a transaction totalling $1,848,750.00. Following the completion of the sale, the director now directly owns 22,840 shares of the company's stock, valued at $2,815,030. Learn More on Hans Rudolf Wigzell's trading history.
Who are Sarepta Therapeutics' active insiders?
Sarepta Therapeutics' insider roster includes Bilal Arif (EVP, Chief Technical Operations Officer), Richard Barry (Director), M. Behrens (Director), Kathryn Boor (Director), Joseph Bratica (Insider), Ryan Brown (EVP), Michael Chambers (Director), Ian Estepan (EVP, Chief Financial Officer), David Howton (EVP), Douglas Ingram (CEO), Stephen Mayo (Director), Dallan Murray (EVP, Chief Customer Officer), Louise Rodino-Klapac (Insider), and Hans Wigzell (Director). Learn More on Sarepta Therapeutics' active insiders.
Are insiders buying or selling shares of Sarepta Therapeutics?
In the last twelve months, Sarepta Therapeutics insiders bought shares 1 times. They purchased a total of 37,038 shares worth more than $4,955,684.40. In the last twelve months, insiders at the biotechnology company sold shares 9 times. They sold a total of 78,532 shares worth more than $11,647,905.42. The most recent insider tranaction occured on August, 30th when CFO Ian Michael Estepan sold 5,985 shares worth more than $822,099.60. Insiders at Sarepta Therapeutics own 7.7% of the company.
Learn More about insider trades at Sarepta Therapeutics. Information on this page was last updated on 8/30/2024.
